Cecchini MJ, et al. - In patients with stage II colon cancer, researchers sought to evaluate whether other markers in the gene signature including CDX1, Muc2, GPX2 and villin could better predict outcome. Investigators found that CDX2 expression was diffusely lost in 11% and focally lost in 23% of cases. Findings revealed that there was no difference in survival based on CDX2 expression, but there was a reduced survival associated with Muc2 loss. No significant outcome differences were identified based on expression of CDX1, GPX2 or villin. Decreased Muc2 expression but not CDX2 was linked to reduced survival in gene expression data from the TCGA. This supports the use of the colonic differentiation gene expression signature to identify patients at high risk, but cautions against the use of any isolated marker based on immunohistochemistry.